[Inflammatory bowel disease during the COVID-19 pandemic: manifestations and management].
Andreas StallmachPhilipp Alexander ReukenPhilip GrunertNiels TeichPublished in: Zeitschrift fur Gastroenterologie (2022)
The COVID-19 pandemic is significantly affecting the lives of patients with inflammatory bowel disease (IBD). Those affected and their relatives have numerous questions about the risk of the disease, the course of a possible SARS-CoV-2 infection or the influence of CED-specific therapy on these. Many IBD patients also have additional questions about the safety and effectiveness of a vaccination against SARS-CoV-2. The aim of this review is to summarize the latest findings on COVID-19 and IBD, but also to discuss vaccine response (humoral/cellular), the influence of ongoing therapy on the vaccine response as well as the frequency of side effects and the importance of booster immunizations and to create an evidence-based basis for discussion with patients.
Keyphrases
- sars cov
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- randomized controlled trial
- peritoneal dialysis
- systematic review
- patients with inflammatory bowel disease
- stem cells
- respiratory syndrome coronavirus
- bone marrow
- ulcerative colitis
- cell therapy
- patient reported